Amphastar Pharmaceuticals, Inc.

NASDAQ:AMPH

Drug Manufacturers - Specialty & Generic

Healthcare
$29.71 -1.60%

-$0.31 today

Market cap
$1.27B
Beta
0.90
P/E (TTM)
10.9
EPS (TTM)
$1.75
52W Low $16.65High $31.26

Volume 0.53M

Average 0.59M

AMPH Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Amphastar Pharmaceuticals, Inc.NASDAQ: AMPH

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $26.74M rose 33.0% year over year, ahead of the +20.2% change in trailing-twelve-month research & development. Sequentially, it rose 14.7% from the prior quarter. Over 3 fiscal years it compounded at +4.7% a year.

Context

  • Research & development amounted to 11.9% of revenue in FY2025, up 1.8 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +33.0% holds above the trailing-twelve-month pace of +20.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$26.74M+14.7% QoQ
Last fiscal yearDec 2025
$85.84M+16.1% YoY
LTMMar 2026
$92.49M+20.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+33.0%——
1 year+16.1%——
3-year CAGR+4.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
85.84M USD
Year-over-year change
+16.1%
4-year CAGR
+8.9%

Research & Development vs competitors

How AMPH compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +20.2% is the 3rd highest of 7, against a peer median of +0.3%.
  • Research & development amounts to 12.8% of revenue for AMPH, versus a peer median of 5.8%.
AMPH Competitors
Research & Development for AMPH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹22.73B INR-13.8%+9.3%6.9%
VTRSViatris Inc.LTM Jun 2026$1.02B USD+20.8%+13.4%6.9%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$995M USD-0.7%+6.5%5.7%
BHCBausch Health Companies Inc.LTM Jun 2026$634M USD+1.3%+5.9%5.8%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$177.66M USD-15.0%-3.7%5.7%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$92.49M USD+20.2%+4.7%12.8%
ETONEton Pharmaceuticals, Inc.LTM Mar 2026$8.48M USD+125.2%+24.8%9.8%
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding AMPH) —+0.3%+7.9%5.8%

Competitors are the stored peer set for AMPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue437.77M498.99M644.4M731.97M719.89M
Cost of Revenue238.03M250.13M293.27M358.11M363.83M
Gross Profit199.74M248.86M351.12M373.86M356.06M
Gross Margin45.6%49.9%54.5%51.1%49.5%
Research & Development60.93M74.77M73.74M73.91M85.84M
Selling, General & Admin68.92M66.59M80.39M94.52M129.81M
Operating Expenses129.85M141.36M154.13M168.44M215.65M
Depreciation & Amortization26.53M28.28M41.78M57.21M63.2M
EBITDA111.56M146.16M240.29M277.31M212.31M
EBITDA Margin25.5%29.3%37.3%37.9%29.5%
Operating Income69.89M107.5M196.99M205.42M140.4M
Operating Margin16.0%21.5%30.6%28.1%19.5%
Interest Income601K1.32M5.46M10.61M8.68M
Interest Expense885K1.85M27.16M30.34M25.48M
Other Income / Expenses14.04M7.37M(27.61M)(16.23M)(16.78M)
Income Before Tax83.93M114.86M169.38M189.19M123.62M
Pre-Tax Margin19.2%23.0%26.3%25.8%17.2%
Income Tax Expense20.63M23.48M31.83M29.67M25.53M
Net Income62.12M91.39M137.55M159.52M98.09M
Net Margin14.2%18.3%21.3%21.8%13.6%
EPS (Basic)1.301.882.853.292.10
EPS (Diluted)1.251.742.603.062.03
Weighted Avg Shares47.78M48.55M48.27M48.43M46.74M
Weighted Avg Shares (Diluted)49.78M52.43M53M52.06M48.22M

Amphastar Pharmaceuticals, Inc.

NASDAQ:AMPH

Intrinsic Alpha fair value

Locked

Current Price

$29.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.